Ambrisentan is a non-sulfonamide, propanoic acid-class, endothelin receptor antagonist that is selective for the endothelin type-A (ETA) receptor.
Gilead Sciences’ decision is based on the interim analysis of unblinded efficacy and safety data by the study’s Data Monitoring Committee (DMC) and review of those data by Gilead, which did not show evidence of a treatment benefit in the group of patients randomized to receive Ambrisentan.
The company is reviewing the data and said that it will communicate the full results of this analysis to the medical community when they are available.